# NewHydrogen, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/NewHydrogen, Inc.). ## Overview NewHydrogen, Inc. is a U.S.-based clean energy technology developer focused on thermochemical green hydrogen production. The company is developing ThermoLoop™ with research support at UC Santa Barbara, and it has also previously worked on material technology for photovoltaic solar modules. ## Products & services • ThermoLoop™ thermochemical water-splitting technology • Green hydrogen production technology development • UC Santa Barbara research collaboration • Photovoltaic solar module material technology - **Thermochemical hydrogen technology** (70%) — Development of ThermoLoop™ and related water-splitting systems for low-cost green hydrogen production. - **Clean energy R&D services** (20%) — Research and development work tied to materials, process design, and prototype advancement. - **Solar materials technology** (10%) — Earlier-stage photovoltaic material technology aimed at improving solar module economics. - ThermoLoop™ thermochemical water-splitting technology - Green hydrogen production technology development - UC Santa Barbara research collaboration - Photovoltaic solar module material technology ## Customers NewHydrogen is primarily a development-stage company, so its direct customer base is limited and not yet commercialized. Its economic stakeholders are likely to include future hydrogen buyers, industrial energy users, and strategic partners that would adopt or license its technology if it reaches commercialization. The company also relies on investors as a funding source while it advances the technology. - **Future industrial hydrogen users** (primary) — Potential buyers of low-cost green hydrogen for fertilizers, refining, steel, and chemicals. - **Strategic partners and licensees** (secondary) — Companies that may collaborate on development, pilot deployment, or commercialization of ThermoLoop™. - **Research and academic collaborators** (secondary) — University and lab partners that help test materials and validate the technology. - **Capital providers** (primary) — Equity investors that fund ongoing R&D and corporate overhead before revenue generation. - Future industrial hydrogen users seeking lower-cost green hydrogen - Energy and process industries needing hydrogen as an input - Potential strategic partners or licensees for the technology - Research collaborators supporting development and validation - Investors funding pre-revenue technology development ## Geography The company is based in the United States and operates from Los Angeles, California. Its current development work is tied to UC Santa Barbara, also in California, which makes its operating footprint concentrated in the U.S. Because the technology targets global hydrogen markets, its eventual commercial opportunity is international even though current operations are domestic. - Headquartered in Los Angeles, California - Development program tied to UC Santa Barbara - Current operations are concentrated in the United States - Target market for hydrogen technology is global - No disclosed country-level revenue because the company has no revenue ## Strategy The company’s near-term strategy is to preserve and advance the ThermoLoop™ development program while managing cash carefully. It is also seeking additional capital from existing and new investors to support prototyping and continued R&D. Longer term, the strategy is to commercialize a lower-cost hydrogen production pathway that can compete with electrolyzer-based green hydrogen. - **Continue ThermoLoop™ development** (short-term) — The company’s value proposition depends on proving the technology can produce hydrogen at lower cost. - **Secure external financing** (short-term) — The company needs capital to fund R&D and general corporate expenses before revenue generation. - **Move toward commercialization** (medium-term) — Commercial adoption is needed to convert the technology platform into a sustainable business. - Maintain ThermoLoop™ development at UC Santa Barbara - Advance prototyping for thermochemical water splitting - Raise additional equity or debt financing - Position the technology as a lower-cost hydrogen pathway - Build optionality for future commercialization or licensing ## Risks The company is pre-revenue and depends on external financing to continue operations, which creates substantial going-concern risk. Its business also depends on technical success in developing ThermoLoop™ and on eventual market acceptance of a new hydrogen production method. As with many early-stage clean technology developers, execution, funding availability, and valuation of equity-linked instruments are key risks. - **Going-concern and financing risk** [critical] — The company has not generated revenue and expects to need additional capital to fund operations. - **Technology development risk** [high] — ThermoLoop™ is still in development, so technical feasibility, scale-up, and cost targets remain uncertain. - **Dilution from equity financing** [high] — Management expects to fund the business through securities issuance, which can dilute existing holders. - **Market adoption risk** [medium] — Even if the technology works, customers may prefer established hydrogen production methods. - **Valuation and estimate risk** [medium] — Fair value estimates for stock options and derivative liabilities can be volatile and judgmental. - No revenue yet, so operations depend on outside capital - Going-concern uncertainty if financing is not available - Technology may not achieve expected performance or cost targets - Commercial adoption risk in a competitive hydrogen market - Dilution risk from future equity financing - Valuation risk from stock-based and derivative instruments ## Accounting The company’s financial statements rely heavily on estimates because it is pre-revenue and development-stage. Key judgment areas include fair value measurement of stock options and derivative liabilities, deferred tax valuation allowance, and impairment testing for long-lived and intangible assets. Because it has no revenue, operating losses, financing flows, and equity-linked valuation assumptions can materially affect reported results. - **Fair value of stock options and derivatives** — Can create volatile non-cash gains or losses - **Impairment of intangible and fixed assets** — Could reduce asset values and increase losses - **Deferred tax valuation allowance** — Affects net deferred tax assets and tax expense - **Going-concern disclosures** — Important for assessing solvency and continuity - No revenue recognition yet because the company is pre-commercial - Fair value of stock options can swing with share price and volatility - Derivative liabilities depend on conversion terms and market inputs - Impairment testing matters for intangible and fixed assets - Deferred tax valuation allowance reflects uncertainty over future profits --- *Last updated: 2026-04-29T04:41:31.413524+00:00*